TICKERNERD
Menu
BSXBSXHealthcare · Medical Devices

BSX Stock Forecast: Boston Scientific Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$52
+0.27% on the day

The 31 Wall Street analysts covering Boston Scientific Corp. hold a median 12-month price target of $60 — +15.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 13 Aug 2026 — in the upper half.

Market cap
$74.9B
Ticker Nerd rank
57 / 100
Median analyst target
$60
Analysts covering
31
Total return, dividends reinvested
1W
+5.1%
1M
+21.6%
YTD
−45.6%
1Y
−50.2%
From 52W high
−52.1%
From 52W low
+21.6%
$43
$108
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BSX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Boston Scientific Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
92
Volatility
90
Quality
90
Growth
84
Issuance
62
Revisions
49
Accruals
37
Momentum
5
Size
4

Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (5): The shares have been drifting down relative to others.

Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BSX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BSX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26BSXHigh $94Median $60Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says31 analysts
26 Buy5 Hold0 Sell
Low $44Median $60High $94

The green dot is the last close — the median target sits +15.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 15 moved it down.

DateFirmActionRatingTarget
31 July 2026Argus ResearchDowngradeHold—
30 July 2026Canaccord GenuityMaintainsBuy$70 → $66
30 July 2026CitigroupMaintainsBuy$70 → $61
30 July 2026Evercore ISI GroupMaintainsOutperform$65 → $55
30 July 2026RBC CapitalMaintainsOutperform$85 → $70
30 July 2026TD CowenMaintainsBuy$61 → $56
30 July 2026Truist SecuritiesMaintainsBuy$62 → $57
30 July 2026UBSMaintainsBuy$74 → $67
30 July 2026Wells FargoMaintainsEqual-Weight$55 → $50
29 July 2026BTIGMaintainsBuy$65 → $60
28 July 2026UBSAssumesBuy$95 → $74
27 July 2026OppenheimerMaintainsOutperform$90 → $85
16 July 2026Truist SecuritiesMaintainsBuy$64 → $62
16 July 2026Truist SecuritiesMaintainsBuy—
15 July 2026MizuhoMaintainsOutperform$90 → $70
15 July 2026MizuhoMaintainsOutperform—
13 July 2026RBC CapitalMaintainsOutperform$100 → $85
13 July 2026RBC CapitalMaintainsOutperform—
8 July 2026NeedhamMaintainsBuy$77 → $57
8 July 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BSX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BSX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−2.2%
Analysts raising
0
Analysts cutting
5
Fundamentals

Boston Scientific Corp. (BSX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.2×

Cheaper than 37% of US stocks

Price / sales
3.6×

Cheaper than 36% of US stocks

Price / book
3.0×

Cheaper than 34% of US stocks

EV / EBITDA
15.3×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
7.5%

Higher than 46% of US stocks

Earnings growth (YoY)
13.8%

Higher than 52% of US stocks

Gross margin
70.7%

Higher than 83% of US stocks

Operating margin
22.9%

Higher than 82% of US stocks

Net margin
17.5%

Higher than 80% of US stocks

Returns & dividend
Return on equity
15.3%

Higher than 75% of US stocks

Return on assets
6.2%

Higher than 82% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BSX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BSXBoston Scientific Corp.$74.9B
57
EWEdwards Lifesciences Corp.$53.3B
91
MDTMedtronic PLC$116.1B
83
SYKStryker Corp.$130.4B
74
DXCMDexCom, Inc.$35.3B
98
GEHCGE Healthcare Technologies, Inc.$33.6B
64
ABTAbbott Laboratories$193.5B
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Boston Scientific Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BSX news & analysis

Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead

Seeking Alpha · 14 Aug 2026positive

Boston Scientific shares have corrected sharply due to slowdowns in its EP and WATCHMAN businesses, but the article notes that 74% of its portfolio continues to grow healthily. The EP weakness is described as addressable through new launches such as FARAWAVE Ultra and ICE, with a recovery anticipated from the second half of 2027 onward.

Why it matters — The piece frames the recent sell-off as driven by addressable, cyclical headwinds within specific segments while emphasizing that the majority of Boston Scientific's portfolio remains resilient, offering context for watchers assessing the company's growth outlook.

Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet

Zacks Investment Research · 13 Aug 2026neutral

Zacks Investment Research published an article discussing whether investors should rely on analyst (brokerage-firm) recommendations when deciding to buy, sell, or hold Boston Scientific stock. The piece notes that media reports about rating changes by sell-side analysts can influence stock prices and questions how much importance such recommendations truly carry.

Why it matters — A Boston Scientific watcher would care because the article weighs the influence of analyst sentiment on BSX's stock price and helps investors gauge how to interpret brokerage ratings.

Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone

Seeking Alpha · 11 Aug 2026positive

Following multiple guidance cuts and a heavy sell-off that left Boston Scientific trading at valuations it author considers attractive relative to peers, the company reported strong Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth. Growth was led by international markets, with electrophysiology up 23.1% and WATCHMAN up 17.7% outside the U.S., offsetting domestic headwinds for those products.

Why it matters — The item argues that the recent sell-off is overdone and highlights resilient international growth, relevant to BSX watchers assessing the company's valuation and momentum after guidance cuts.

Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?

The Motley Fool · 10 Aug 2026neutral

Boston Scientific director Habiger purchased 2,100 shares of BSX for approximately $100,000 on August 5, 2026, increasing his total direct equity holdings by 14%. The purchase comes amid a 54% decline in the stock's price.

Why it matters — An insider purchase of this size by a director may be of interest to BSX watchers as a signal about management's view of the stock, particularly following its sharp decline.

Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?

The Motley Fool · 10 Aug 2026positive

Boston Scientific CEO Michael F. Mahoney spent approximately $10.0 million on August 3, 2026, to buy roughly 200,000 shares at a weighted average price of $48.34, increasing his total equity holdings by 13% and expanding his direct stake in the company.

Why it matters — A sizeable insider purchase by the CEO typically signals management confidence, which investors tracking BSX would note when assessing company direction.

FAQ

Frequently asked questions about BSX stock

What is the BSX stock price forecast for 2026-2027?

The 31 Wall Street analysts covering Boston Scientific Corp. have a median 12-month price target of $60, with estimates ranging from $44 to $94. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BSX stock a buy right now?

Of the 31 analysts covering Boston Scientific Corp., 26 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Boston Scientific Corp. 57 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BSX?

As at 13 Aug 2026, Boston Scientific Corp. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).

Will BSX stock go up?

No one can know that. What the data says: the median 12-month target from 31 analysts implies +15.8% from the last close, and Ticker Nerd's factor model ranks Boston Scientific Corp. 57 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BSX stock forecast for 2030?

No analyst covering Boston Scientific Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BSX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $94 over the next 12 months.

How has BSX stock performed over the past year?

Boston Scientific Corp. returned -50.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Boston Scientific Corp. do?

Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets a broad portfolio of minimally invasive medical devices. The company focuses on devices used in cardiovascular care, structural heart therapies, electrophysiology, peripheral interventions, and cardiac rhythm management, as well as solutions for endoscopy, urology, pelvic health, pain management, and neuromodulation.

What is the latest news on BSX?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead". Boston Scientific shares have corrected sharply due to slowdowns in its EP and WATCHMAN businesses, but the article notes that 74% of its portfolio continues to grow healthily. The EP weakness is described as addressable through new launches such as FARAWAVE Ultra and ICE, with a recovery anticipated from the second half of 2027 onward.

Company

About Boston Scientific Corp.

Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets a broad portfolio of minimally invasive medical devices. The company focuses on devices used in cardiovascular care, structural heart therapies, electrophysiology, peripheral interventions, and cardiac rhythm management, as well as solutions for endoscopy, urology, pelvic health, pain management, and neuromodulation. Its products include implants, catheters, mapping and ablation systems, diagnostic tools, and various disposable instruments that are used by clinicians during interventional procedures. Boston Scientific organizes its operations into major business segments such as Cardiovascular and MedSurg, reflecting its concentration in heart and vascular therapies alongside surgical and specialty care areas like endoscopy and urology. The company serves hospitals, clinics, outpatient facilities, and physician offices in approximately 130 countries, distributing products directly and through specialized medical device channels. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific today plays a central role in enabling modern, procedure-based care across multiple therapeutic specialties worldwide.

CEO Mr. Michael F. Mahoney · 59,000 employees · United States · https://www.bostonscientific.com